The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

Witty’s departure was unexpected, but follows a downturn in the healthcare company’s financial outlook. He will be replaced ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...